203 related articles for article (PubMed ID: 2226679)
21. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
22. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
24. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts.
Yamazaki T; Sato Y; Sieber F
Exp Hematol; 1997 Jul; 25(7):629-37. PubMed ID: 9216739
[TBL] [Abstract][Full Text] [Related]
25. Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.
Lagneaux L; Marie JP; Delforge A; Socquet M; Thevenin D; Zittoun R; Stryckmans P
Exp Hematol; 1989 Aug; 17(7):843-6. PubMed ID: 2753092
[TBL] [Abstract][Full Text] [Related]
26. Etoposide-induced cytotoxicity in two human T-cell leukemic lines: delayed loss of membrane permeability rather than DNA fragmentation as an indicator of programmed cell death.
Catchpoole DR; Stewart BW
Cancer Res; 1993 Sep; 53(18):4287-96. PubMed ID: 8364925
[TBL] [Abstract][Full Text] [Related]
27. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells.
Gosland MP; Lum BL; Sikic BI
Cancer Res; 1989 Dec; 49(24 Pt 1):6901-5. PubMed ID: 2582432
[TBL] [Abstract][Full Text] [Related]
28. Relationship of VP-16 to the classical multidrug resistance phenotype.
Sehested M; Friche E; Jensen PB; Demant EJ
Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F
Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
[TBL] [Abstract][Full Text] [Related]
31. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
32. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
33. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
[TBL] [Abstract][Full Text] [Related]
34. 17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter.
Gosland M; Tsuboi C; Hoffman T; Goodin S; Vore M
Cancer Res; 1993 Nov; 53(22):5382-5. PubMed ID: 8106146
[TBL] [Abstract][Full Text] [Related]
35. Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.
Soudon J; Berlion M; Lucas C; Haddad P; Bizzari JP; Calvo F
Cancer Chemother Pharmacol; 1995; 36(3):195-203. PubMed ID: 7781138
[TBL] [Abstract][Full Text] [Related]
37. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.
Cairo MS; Siegel S; Anas N; Sender L
Cancer Res; 1989 Feb; 49(4):1063-6. PubMed ID: 2536292
[TBL] [Abstract][Full Text] [Related]
38. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging.
Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D
Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495
[TBL] [Abstract][Full Text] [Related]
39. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
40. Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model.
Kühl JS; Sikic BI; Blume KG; Chao NJ
Prog Clin Biol Res; 1992; 377():25-34. PubMed ID: 1438422
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
